• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Roivant Sciences Ltd (NQ: ROIV )

    11.87 +0.11 (+0.94%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Roivant Sciences Ltd

    < Previous 1 2 3 4 5 6 7 8 Next >
    Why Did Pfizer Offload This Potential Mega-Blockbuster Drug?
    Pfizer's decision to offload a potential mega-blockbuster may seem counterintuitive, but the drugmaker appears to have solid reasons for doing so. 
    Via The Motley Fool
    Why Shares of Roivant Sciences Jumped This Week
    The company's stock benefited from another company's buyout. 
    Via The Motley Fool
    These 2 Growth Stocks Might Be Incredibly Undervalued Right Now
    These two biopharma stocks could be poised for a major growth spurt. 
    Via The Motley Fool
    EXCLUSIVE: Joe Biden Tops 2024 Election Betting Odds, How Negative Headlines And Indictment Move Trump Ahead Of DeSantis
    While the 2024 U.S. presidential election may seem a long way off, polls to see who is favored by voters and betting odds for the next White House occupant have ramped up. 
    Via Benzinga
    These 3 Nasdaq Stocks Are on Fire Today: Here's Why
    A high-dollar buyout is lighting a fire underneath these three Nasdaq stocks today. 
    Via The Motley Fool
    Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom
    Merck is branching into immune-mediated diseases with this takeover. 
    Via Investor's Business Daily
    Analyst Expectations for Roivant Sciences's Future
    Via Benzinga
    Roivant Sciences Highlights Topline Data From Atopic Dermatitis Drug In Patients As Young As 2 Years
    Via Benzinga
    Expert Ratings for Roivant Sciences
    Via Benzinga
    Prometheus Biosciences, XPeng And Other Big Stocks Moving Higher In Monday's Pre-Market Session
    U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 70.1% to $193.93... 
    Via Benzinga
    Lokavant Hires Experienced Leaders to Accelerate Growth Trajectory
    From Lokavant
    Via Business Wire
    Lokavant Emerges from Roivant Sciences with Multiple Industry Partnerships to Accelerate Impact on Clinical Research
    From Lokavant
    Via Business Wire
    Roivant Sciences's Earnings Outlook
    Via Benzinga
    7 Biotech Stocks to Buy for Breakthrough Treatments and Cures
    For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine. 
    Via InvestorPlace
    Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients
    From Covant Therapeutics
    Via GlobeNewswire
    Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Gainers U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share. 
    Via Benzinga
    Why Shares of Roivant Sciences Were Down Tuesday
    After a run-up last week prompted by positive clinical trial results, the stock has given back its recent gains. 
    Via The Motley Fool
    The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
    To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
    Via InvestorPlace
    Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
    From Roivant Sciences
    Via GlobeNewswire
    Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis
    From Roivant Sciences
    Via GlobeNewswire
    Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs
    PVTX-321 and PVTX-405 Achieve Development Candidate Nomination 
    From Roivant Sciences
    Via GlobeNewswire
    Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement
    From Roivant Sciences
    Via GlobeNewswire
    Roivant Sciences Announces Change to its Board of Directors
    From Roivant Sciences
    Via GlobeNewswire
    Immunovant Could Potentially Be An M&A Target, Writes Analyst
    Via Benzinga
    Mixed Signals On Valentine's Day: How Stocks Are Reacting To January Inflation Data
    Inflation cooled slightly in January, but saw increases in some areas due to the impact of surging food, energy and shelter prices on consumers, the U.S Labor Department said Tuesday.  
    Via Benzinga
    Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update
    From Roivant Sciences
    Via GlobeNewswire
    Earnings Scheduled For February 13, 2023
    Companies Reporting Before The Bell • EuroDry (NASDAQ:EDRY) is expected to report quarterly earnings at $2.68 per share on revenue of $21.20 million. 
    Via Benzinga
    Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares
    From Roivant Sciences
    Via GlobeNewswire
    Roivant Sciences Announces Proposed Public Offering of Common Shares
    From Roivant Sciences
    Via GlobeNewswire
    Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023
    From Roivant Sciences
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.